Non-Consolidated Financial Results (Japanese GAAP)
for the Three Months Ended March 31, 2026

May 14, 2026

Company Name: Chiome Bioscience Inc. Tokyo Stock Exchange
Stock Code: 4583 URL https://www.chiome.co.jp
Representative: Masamichi Koike, President & CEO
Inquiries: Miseri Tanaka, Head of Corporate Division TEL: +81-3-6383-3561
Scheduled dividend payment commencement date: —
Supplementary materials prepared for the quarterly financial results: Yes
Holding of the quarterly financial results explanatory meeting: No

(Amounts of less than one million yen are rounded down)

1. Financial Results for the Three Months Ended March 31, 2026 (January 1, 2026 to March 31, 2026)

(1) Operating Results (Cumulative)

(% figures are the increase / (decrease) compared with the corresponding period of the previous fiscal year)

	Net Sales		Operating Income		Ordinary Income		Net Income	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Three months ended Mar. 31, 2026	147	6.1	(232)	—	(232)	—	(233)	—
Three months ended Mar. 31, 2025	138	7.0	(264)	—	(265)	—	(266)	—

	Net Income per Share	Diluted Net Income per Share
	Yen	Yen
Three months ended Mar. 31, 2026	(3.31)	—
Three months ended Mar. 31, 2025	(3.94)	—

Notes: Despite the existence of shares with a dilutive effect, "Diluted Net Income per Share" is not stated because Chiome incurred a loss for each respective period.

(2) Financial Position

	Total Assets	Net Assets	Equity Ratio
	Million yen	Million yen	%
As of Mar. 31, 2026	1,670	1,311	78.0
As of Dec. 31, 2025	1,727	1,122	64.1

(Reference) Equity As of Mar. 31, 2026: 1,302 million yen As of Dec. 31, 2025: 1,107 million yen

2. Dividends

	Annual Dividends				
	1Q-End	2Q-End	3Q-End	FY-End	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal Year Ending Dec. 31, 2025	—	0.00	—	0.00	0.00
Fiscal Year Ending Dec. 31, 2026	—				
Fiscal Year Ending Dec. 31, 2026 (Forecast)		0.00	—	0.00	0.00

Note: Revision to the most recently announced dividend forecast: No

3. Forecasts of Financial Results for the Fiscal Year Ending December 31, 2026 (January 1, 2026 to December 31, 2026)

As it is difficult to provide reasonable estimates for Drug Discovery and Development Business at present, Chiome discloses only business forecasts for Drug Discovery Support Business (net sales of ¥600 million). There is no revision to the most recently announced forecasts of financial results.

[Notes]

(1) Application of Special Accounting Practices in the Preparation of Quarterly Financial Statements: No

(2) Changes in Accounting Policies, Changes in Accounting Estimates, and Retrospective Restatements
- 1) Changes in accounting policies in line with revisions to accounting and other standards: No
- 2) Changes in accounting policies other than 1) above: No
- 3) Changes in accounting estimates: No
- 4) Retrospective restatements: No

(3) Number of Shares Issued (Common Stock)

1) Number of shares issued as of the end of the period (including treasury stock)	As of Mar. 31, 2026	72,651,300 shares	As of Dec. 31, 2025	68,453,800 shares
2) Number of treasury stock as of the end of the period	As of Mar. 31, 2026	22,729 shares	As of Dec. 31, 2025	12,149 shares
3) Average number of shares for the period (cumulative total for the period)	Three months ended Mar. 31, 2026	70,397,006 shares	Three months ended Mar. 31, 2025	67,579,073 shares

*This summary report on Chiome's quarterly financial statements is not subject to quarterly review procedures.

* Explanation Concerning the Proper Use of Financial Results Forecasts and Other Relevant Specific Items

Forward-looking statements including forecasts of financial results contained in this report are based on management's assumptions and beliefs that are determined to be reasonable in light of currently available information. Chiome cautions readers that due to a variety of factors actual results may differ materially from forecasts. For the assumptions that underpin financial results forecasts as well as other related items, please refer to the "1. Qualitative Information Regarding Quarterly Financial Results (3) Explanation of Forward-Looking Statements including Forecasts of Financial Results" on page 4 of this report.

Contents

1. Qualitative Information Regarding Quarterly Financial Results

(1) Overview of Operating Results

The Company operates a drug discovery business, mainly developing antibody drugs for areas with high unmet needs, utilizing its antibody generation technology and drug discovery expertise. The Company also operates a drug discovery support business that offers drug discovery technologies and capabilities based on experience and know-how, such as antibody generation and protein expression/purification to pharmaceutical companies and academic institutions.

An overview of the Company's business activities for the first quarter ended March 31, 2026 is as follows.

In the drug discovery business, Phase I clinical studies are underway for CBA-1535 and CBA-1205; both are in-house developed therapeutic antibodies for cancer. For CBA-1205, patient dosing is currently underway for patients with melanoma, hepatocellular carcinoma, and pediatric cancers in the second part of the study. For CBA-1535, a multispecific antibody targeting cancer, the Company is conducting a stepwise dose-escalation study in patients with solid tumors to evaluate its safety. For other drug discovery pipeline products, the Company continues introductions, scientific validation, and discussions with potential out-licensing partners.

In the drug discovery support business, while focusing on maintaining strong relationships with existing major clients, the Company continues to promote activities to stabilize its revenue base during the quarter.

In the IDD business launched in the previous fiscal year, which is a platform-based initiative for antibody drug discovery, we are progressing biosimilar related business with Alfresa Holdings Corporation (Alfresa Holdings) and Kidswell Bio Corporation (Kidswell) and are steadily advancing the joint development of new cell line development for biosimilars. Furthermore, we are exploring partnerships and engaging in discussions with pharmaceutical companies to advance the launch of biosimilars under development and to develop additional biosimilars.

At the same time, discussions with potential business partners are progressing to secure additional research and clinical projects. We will continue our efforts to apply our drug discovery technologies to biopharmaceutical drug discovery.

The Company's performance for the first quarter is as follows: net sales of ¥147,162 thousand (an increase of ¥8,462 thousand year on year), R&D expenses of ¥174,471 thousand (a decrease of ¥29,321 thousand year on year), operating loss of ¥232,346 thousand (operating loss of ¥264,560 thousand in the same period last year), ordinary loss of ¥232,341 thousand (ordinary loss of ¥265,606 thousand in the same period last year), and quarterly net loss of ¥233,151 thousand (quarterly loss of ¥266,066 thousand in the same period last year). As R&D expenses, particularly clinical development costs, decreased, operating loss, ordinary loss and quarterly net loss all decreased compared with the same period last year.

An overview of the Company's business activities for the first quarter by segment is as follows.

・Drug Discovery Business

- Drug Discovery Pipeline (out-licensed products)

PFKR is a therapeutic antibody candidate for autoimmune disease in CNS area targeting CX3CR1, a type of G protein-coupled receptor (GPCR). The company and the National Center of Neurology and Psychiatry are progressing with a joint research program. In November 2024, the company entered into license agreement with

Asahi Kasei Therapeutics Corporation (formerly Asahi Kasei Pharma Corporation), which is currently preparing for the initiation of preclinical studies.

- Drug Discovery Pipeline (main in-house programs, out-licensing candidates)

For CBA-1205, the Company is conducting the second part of the Phase I clinical study in Japan. The primary objective of the study is to evaluate safety and tolerability of CBA-1205 in cancer patients. The first part of the study is for patients with solid tumors, and the second part is for patients with melanoma, hepatocellular carcinoma and pediatric cancers. Patient enrollment for the first part has been completed, and CBA-1205 demonstrated a favorable safety profile at doses up to 30mg/kg. Notably, a melanoma patient enrolled in the first part has maintained stable disease (SD) assessment with tumor shrinkage for more than 4 years. In the second part, patient enrollment for melanoma and hepatocellular carcinoma has been completed and evaluation of patients who continued treatment and analysis of the data are currently ongoing. As in the first part, CBA-1205 demonstrated a favorable safety profile. In a patient with confirmed expression of DLK1, tumour shrinkage of more than 30% (PR) has been observed. Currently, patient enrollment for pediatric cancers is in progress. The evaluation of safety and tolerability of pediatric cancer patients with confirmed expression of DLK1 at screening is ongoing. In the screening test up to date, high frequency of DLK1 expression has been observed. Safety evaluation of the initial dose cohort has been completed, and that of the high dose cohort is currently underway.

A Phase I clinical study of CBA-1535 in patients with solid tumors is also underway in Japan. At present, evaluation for the safety and tolerability of CBA-1535 as a single agent is in progress and no adverse events raising development concerns have been observed. The clinical study remains ongoing with dose escalation. While we are planning to combine CBA-1535 with a checkpoint inhibitor after confirming the efficacy signals as a single agent, we will prioritize initiatives such as future out-licensing utilizing the clinical data from the single agent study as we advance our business activities going forward.

PTRY is a Tribody® antibody and is expected to add immune checkpoint inhibitory function on the T-cell engager function of CBA-1535. Its initial evaluations using animal models have shown strong anti-tumor effects. For the development of this product, we have decided to prioritize out-licensing to other pharmaceutical companies who can enter commercialization and clinical development rather than carrying out early clinical development by ourselves. This is because we can expect licensing out in pre-clinical stages, depending on the development status of CBA-1535.

For PCDC, we are conducting out-licensing activities for PCDC, a humanized anti-CDCP1 antibody, with a focus on antibody drug conjugate (ADC) applications. Amid growing global interest in ADCs, we are promoting out-licensing activities with pharmaceutical companies that own ADC technologies.

PXLR is a humanized antibody targeting CXCL1 for cancer therapy. CXCL1 is highly expressed in cancers such as gastric and pancreatic cancers. It is a new candidate for out-licensing, and a joint research program with Osaka Metropolitan University is in progress.

We are also advancing initiatives to strengthen our pipeline with new projects such as initiation of collaborative research for the development of mRNA-encoded antibodies utilizing Tribody®, as well as advancing out-licensing activities in drug discovery projects that are in the exploratory phase.

➢ IDD Business

The Company has been promoting the creation of drug seeds and making them into intellectual property to expand our pipeline and explore out-licensing opportunities. In addition, it aims to enhance profitability through this IDD business that utilizes its antibody drug discovery technology and know-how. The Company is focused on establishing new collaborations with pharmaceutical companies and startups in drug discovery research and/or biosimilar development. At present, discussions have commenced with potential partners aimed at securing new business opportunities.

As a result of the above, segment results for the first quarter in the drug discovery business are as follows: R&D expenses of ¥174,471 thousand due to the progress of clinical development (a decrease of ¥29,321 thousand year on year), and segment loss of ¥174,471 thousand (segment loss of the same period last year was ¥203,792 thousand).

・Drug Discovery Support Business

The drug discovery support business contributes to the company's stable earnings. It provides research support services by undertaking antibody production utilizing its proprietary antibody generation platform, and protein preparation works mainly utilizing its protein purification technologies. The Company supports biopharmaceutical research mainly for major domestic pharmaceutical companies such as Ono Pharmaceutical Co., Ltd. and Chugai Pharmaceutical Co., Ltd. The Company's service capabilities are highly recognized by its client companies. Efforts to stabilize the revenue base are ongoing. The revenue from collaboration work on cell line development for a biosimilar with Alfresa Holdings and Kidswell is recorded as revenue for this business.

The results for the first quarter in the drug discovery support business are as follows: net sales of ¥147,162 thousand (an increase of ¥8,462 thousand year on year), segment profit of ¥80,520 thousand (a decrease of ¥121 thousand year on year) segment profit margin of 54.7% (target 50%).

(2) Overview of Financial Position

(Assets)

Total net assets at the end of the first quarter amounted ¥1,670,208 thousand, a decrease of ¥57,296 thousand compared with the end of the previous fiscal year. This was mainly due to a decrease in cash and deposits.

(Liabilities)

Total liabilities at the end of the first quarter amounted ¥358,223 thousand, a decrease of ¥247,217 thousand compared with the end of the previous fiscal year. This decrease was mainly due to the redemption of corporate bonds.

(Net assets)

Total net assets at the end of the first quarter amounted ¥1,311,985 thousand, an increase of ¥189,921 thousand compared with the end of the previous fiscal year. While retained earnings decreased due to a quarterly net loss, this was mainly due to increases in share capital and capital reserve from the exercise of stock acquisition rights.

(3) Explanation of Forward-Looking Statements including Forecasts of Financial Results

There are no changes to the financial results forecasts for the year ending December 31, 2026, announced on February 10, 2026.

The impact of the Middle East situation on the Company's business is expected to be minimal as of now.

2. Quarterly Financial Statements

(1) Quarterly Balance Sheets

Thousand yen

	As of Dec. 31, 2025	As of Mar. 31, 2026
Assets		
Current assets		
Cash on hand and in banks	1,205,026	1,141,514
Accounts receivable	71,996	55,518
Inventories	49,412	44,742
Advance payment-trade	135,015	156,730
Consumption taxes receivable	29,520	6,020
Other current assets	55,726	88,103
Total current assets	1,546,698	1,492,630
Non-current assets		
Property and equipment		
Machinery	250,121	252,330
Accumulated depreciation	(213,781)	(215,648)
Machinery, net	36,340	36,682
Tools and equipment	79,857	79,744
Accumulated depreciation	(79,857)	(79,744)
Tools and equipment, net	0	0
Total property and equipment	36,340	36,682
Investments and other assets		
Long-term prepaid expenses	16,274	12,704
Lease deposits and others	128,191	128,191
Others	0	0
Total investments and other assets	144,465	140,895
Total non-current assets	180,806	177,578
Total assets	1,727,504	1,670,208

Thousand yen

	As of Dec. 31, 2025	As of Mar. 31, 2026
Liabilities		
Current liabilities		
Accounts payable, trade	37,442	34,743
Short-term borrowings	86,700	86,700
Accounts payable, other	82,517	62,329
Accrued expenses	14,555	10,992
Income taxes payable	12,553	5,791
Contract liabilities	130,329	96,437
Deposits received	10,787	5,564
Total Current liabilities	374,885	302,559
Non-current liabilities		
Asset retirement obligations	55,554	55,663
Bonds payable	175,000	－
Total non-current liabilities	230,554	55,663
Total liabilities	605,440	358,223
Net assets		
Shareholders' equity		
Capital stock	1,085,523	1,299,373
Capital reserve	2,025,797	2,239,647
Retained earnings	(2,003,555)	(2,236,707)
Treasury stock	(292)	(301)
Total shareholders' equity	1,107,473	1,302,011
Subscription rights to shares	14,591	9,973
Total net assets	1,122,064	1,311,985
Total liabilities and net assets	1,727,504	1,670,208

(2) Quarterly Statement of Income

(First Quarter Cumulative)

Thousand yen

	Three Months Ended Mar. 31, 2025 (Jan. 1, 2025 to Mar. 31, 2025)	Three Months Ended Mar. 31, 2026 (Jan. 1, 2026 to Mar. 31, 2026)
Net sales	138,699	147,162
Cost of sales	58,056	66,641
Gross profit	80,642	80,520
Selling, general and administrative expenses		
Research and development expenses	203,792	174,471
Other, net	141,410	138,395
Total selling, general and administrative expenses	345,203	312,867
Operating loss	(264,560)	(232,346)
Non-operating income		
Interest income	722	1,031
Foreign exchange gains	568	245
Other, net	90	38
Total non-operating income	1,381	1,315
Non-operating expenses		
Interest expenses	905	292
Share issuance cost	1,521	1,017
Other, net	—	0
Total non-operating expenses	2,426	1,309
Ordinary loss	(265,606)	(232,341)
Extraordinary income		
Gain on reversal of share acquisition rights	350	—
Total extraordinary income	350	—
Loss before income taxes	(265,256)	(232,341)
Income taxes-current	810	810
Total income taxes	810	810
Net loss	(266,066)	(233,151)

(3) Notes Concerning Quarterly Financial Statements

(Notes Regarding Going Concern Assumptions)

Not applicable.

(Notes Regarding Substantial Changes in Shareholders' Equity)

During the first cumulative period, the balance of capital stock and capital reserve increased separately by 213,849 thousand due to exercise of the Subscription Rights to Shares. As a result, as of March 31, 2026, the balance of capital stock and capital reserve came to ¥1,299,373 thousand and ¥2,239,647 thousand, respectively.

(Notes to quarterly cash flow statement)

The cash flow statement for the three months is not present herein. Depreciation and amortization for the three months are as follows.

(Thousand yen)

	Three Months Ended Mar. 31, 2025 (Jan.1, 2025 to Mar. 31, 2025)	Three Months Ended Mar. 31, 2026 (Jan. 1, 2026 to Mar. 31, 2026)
Depreciation and amortization	—	2,326

(Segment information)

The Three Months Ended March 31, 2025 (January 1, 2025 to March 31, 2025)

(Thousand yen)

	Reportable Segments		Total	Adjustments (Note 1)	Amount Recorded on the Balance Sheet (Note 2)
	Drug Discovery and Development Business	Drug Discovery Support Business			
Net sales					
Goods or services transferred at one point of time	—	49,951	49,951	—	49,951
Goods or services transferred over a period of time	—	88,747	88,747	—	88,747
Revenue from contracts with customers	—	138,699	138,699	—	138,699
Sales to external customers	—	138,699	138,699	—	138,699
Internal sales or exchange between segments	—	—	—	—	—
Total	—	138,699	138,699	—	138,699
Segment income (loss)	(203,792)	80,642	(123,149)	(141,410)	(264,560)

Notes:

1. Details regarding adjustments are presented as follows:
   (1) Adjustments to segment income (loss) are selling, general and administrative expenses that relate to areas other than research and development.

(2) Segment assets are not allocated between segments because all assets of the Company are unified in their generation of cash flows and apply to multiple antibody generation technologies. Accordingly, the amount of total assets recorded on the balance sheet is presented as the adjustment balance.

2. The total amount of segment income (loss) is reconciled with operating loss recorded in the statement of income.

The Three Months Ended March 31, 2026 (January 1, 2026 to March 31, 2026)

(Thousand yen)

	Reportable Segments		Total	Adjustments (Note 1)	Amount Recorded on the Balance Sheet (Note 2)
	Drug Discovery and Development Business	Drug Discovery Support Business			
Net sales					
Goods or services transferred at one point of time	—	35,927	35,927	—	35,927
Goods or services transferred over a period of time	—	111,235	111,235	—	111,235
Revenue from contracts with customers	—	147,162	147,162	—	147,162
Sales to external customers	—	147,162	147,162	—	147,162
Internal sales or exchange between segments	—	—	—	—	—
Total	—	147,162	147,162	—	147,162
Segment income (loss)	(174,471)	80,520	(93,950)	(138,395)	(232,346)

Notes:

1. Details regarding adjustments are presented as follows:
   (1) Adjustments to segment income (loss) are selling, general and administrative expenses that relate to areas other than research and development.
   (2) Segment assets are not allocated between segments because all assets of the Company are unified in their generation of cash flows and apply to multiple antibody generation technologies. Accordingly, the amount of total assets recorded on the balance sheet is presented as the adjustment balance.
2. The total amount of segment income (loss) is reconciled with operating loss recorded in the statement of income.

(Important subsequent events)

Capital Increase Attributed to the Exercise of Subscription Rights to Shares

After the end of the current fiscal year and up to April 30, 2026, a portion of the 23rd stock acquisition rights were exercised. The summary of the exercised stock acquisition rights is as follows.

(1) Type and number of shares issued: Common stock, 1,808,000 shares

(2) Increased capital stock: ¥85,668 thousand

(3) Increased legal capital reserve: ¥85,668 thousand

As a result, as of April 30, 2026, the total number of the common stock issued is 74,459,300 shares. The capital stock and capital reserve are ¥1,385,041 thousand and ¥2,325,315 thousand respectively